Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Rhea-AI Summary

Ocugen (NASDAQ: OCGN) announced that CEO Dr. Shankar Musunuri will present at the Oppenheimer Movers in Rare Disease Summit on December 12, 2024, at the Westin Grand Central, New York. The presentation will focus on the company's progress in developing modifier gene therapies for inherited retinal diseases.

Dr. Musunuri will discuss two key programs: the Phase 3 OCU400 liMeliGhT clinical trial for retinitis pigmentosa (RP) and the Phase 1/2 OCU410ST GARDian clinical trial for Stargardt disease. The presentation is scheduled for 2:45-3:30 p.m. ET in the Grand Central Ballroom C&D. Company executives will also conduct one-on-one meetings with investors to discuss business and clinical development strategies.

MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen will present at the Oppenheimer Movers in Rare Disease Summit at the Westin Grand Central, New York on Thursday, December 12, 2024.

“I have witnessed firsthand the impact that Ocugen’s modifier gene therapies have made in the lives of patients with retinitis pigmentosa (RP) and Stargardt disease, which are inherited retinal diseases with significant unmet medical need,” said Dr. Musunuri. “In the coming months, I cannot wait to share more data about these two exciting programs—the Phase 3 OCU400 liMeliGhT clinical trial for RP and Phase 1/2 OCU410ST GARDian clinical trial for Stargardt disease.”

Session: Elevator Pitches from Rare Disease Companies with Key Near-term, Potentially Stock-moving Catalysts

Location: Grand Central Ballroom C&D

Time: 2:45-3:30 p.m. ET

In addition to Dr. Musunuri’s session, members of Ocugen’s executive team will conduct one-on-one meetings with investors to highlight the Company’s business and clinical development strategy.

About Ocugen, Inc. 
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patients’ lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
Head of Communications
Tiffany.Hamilton@ocugen.com

FAQ

What clinical trials will Ocugen (OCGN) discuss at the Oppenheimer Summit on December 12, 2024?

Ocugen will discuss two clinical trials: the Phase 3 OCU400 liMeliGhT trial for retinitis pigmentosa and the Phase 1/2 OCU410ST GARDian trial for Stargardt disease.

What are the target diseases for Ocugen's (OCGN) gene therapy programs?

Ocugen's gene therapy programs target two inherited retinal diseases: retinitis pigmentosa (RP) and Stargardt disease, both of which have significant unmet medical needs.

When and where will Ocugen (OCGN) present at the Oppenheimer Rare Disease Summit?

Ocugen will present on Thursday, December 12, 2024, from 2:45-3:30 p.m. ET at the Westin Grand Central in New York, specifically in the Grand Central Ballroom C&D.

What investment opportunities will be available at the Oppenheimer Summit for OCGN investors?

Ocugen's executive team will conduct one-on-one meetings with investors to discuss the company's business and clinical development strategy.